1
|
White CR, Palgunachari M, Wolkowicz P, Anantharamaiah GM. Peptides as Therapeutic Agents for Atherosclerosis. Methods Mol Biol 2022; 2419:89-110. [PMID: 35237960 DOI: 10.1007/978-1-0716-1924-7_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
More than three decades ago, as a test for the amphipathic helix theory, an 18 amino acid residue peptide and its analogs were designed with no sequence homology to any of the exchangeable apolipoproteins. Based on the apolipoprotein A-I (the major protein component of high density lipoproteins, HDL) mimicking properties, they were termed as ApoA-I mimicking peptides. Several laboratories around the world started studying such de novo-designed peptides for their antiatherogenic properties. The present chapter describes the efforts in bringing these peptides as therapeutic agents for atherosclerosis and several lipid-mediated disorders.
Collapse
Affiliation(s)
- C Roger White
- Department of Medicine, UAB Medical Centre, Birmingham, AL, USA
| | | | - Paul Wolkowicz
- Department of Medicine, UAB Medical Centre, Birmingham, AL, USA
| | | |
Collapse
|
2
|
Cochran BJ, Ong KL, Manandhar B, Rye KA. APOA1: a Protein with Multiple Therapeutic Functions. Curr Atheroscler Rep 2021; 23:11. [PMID: 33591433 DOI: 10.1007/s11883-021-00906-7] [Citation(s) in RCA: 67] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/08/2021] [Indexed: 01/11/2023]
Abstract
PURPOSE OF THE REVIEW Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states. RECENT FINDINGS Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.
Collapse
Affiliation(s)
- Blake J Cochran
- Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia
| | - Kwok-Leung Ong
- Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia
| | - Bikash Manandhar
- Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia
| | - Kerry-Anne Rye
- Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia.
| |
Collapse
|
3
|
Hamid T, Ismahil MA, Bansal SS, Patel B, Goel M, White CR, Anantharamaiah GM, Prabhu SD. The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction. Int J Mol Sci 2020; 21:ijms21103519. [PMID: 32429244 PMCID: PMC7279031 DOI: 10.3390/ijms21103519] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 05/12/2020] [Accepted: 05/13/2020] [Indexed: 01/01/2023] Open
Abstract
Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects after myocardial infarction (MI) is unknown. Here we demonstrate that L-4F suppresses the expansion of blood, splenic, and myocardial pro-inflammatory monocytes and macrophages in a mouse model of reperfused MI. Changes in immune cell profiles were accompanied by alleviation of post-MI LV remodeling and dysfunction. In vitro, L-4F also inhibited pro-inflammatory and glycolytic gene expression in macrophages. In summary, L-4F treatment prevents prolonged and excessive inflammation after MI, in part through modulation of pro-inflammatory monocytes and macrophages, and improves post-MI LV remodeling. These data suggest that L-4F could be a used as a therapeutic adjunct in humans with MI to limit inflammation and alleviate the progression to heart failure.
Collapse
Affiliation(s)
- Tariq Hamid
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
- Correspondence: (T.H.); (S.D.P.)
| | - Mohamed Ameen Ismahil
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
| | - Shyam S. Bansal
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
| | - Bindiya Patel
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
| | - Mehak Goel
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
| | - C. Roger White
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
| | - G. M. Anantharamaiah
- Division of Gerontology, Geriatrics, and Palliative Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA;
| | - Sumanth D. Prabhu
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (M.A.I.); (S.S.B.); (B.P.); (M.G.); (C.R.W.)
- Medical Service, Birmingham VAMC Birmingham, Birmingham, AL 35233, USA
- Correspondence: (T.H.); (S.D.P.)
| |
Collapse
|
4
|
Bourdi M, Amar M, Remaley AT, Terse PS. Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys. Regul Toxicol Pharmacol 2018; 100:59-67. [PMID: 30359697 PMCID: PMC6893859 DOI: 10.1016/j.yrtph.2018.10.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 10/19/2018] [Accepted: 10/20/2018] [Indexed: 01/22/2023]
Abstract
Fx-5A peptide complex (Fx-5A), a High Density Lipoproteins (HDL) mimetic, has been shown to reduce atherosclerosis. The safety and toxicokinetics of Fx-5A administered IV by 30 min infusion at 8, 25 or 75 mg/kg body weight or vehicle, once every other day for 27 days, were assessed in cynomolgus monkeys. The Fx-5A was well tolerated at all doses. At the highest dose, there were statistically significant effects on hematology and clinical chemistry parameters that were considered non-adverse. Dose-dependent recoverable non-adverse erythrocytes morphological changes (acanthocytes, echinocytes, spherocytes, microcytes, and/or schistocytes) were observed. Fx-5A was not hemolytic in in-vitro fresh NHP or human blood assay. There were no Fx-5A-related statistically significant changes for any cardiovascular function, ECG or respiratory parameters, when compared to control. In addition, there were no Fx-5A-related effects on organ weights, macroscopic or microscopic endpoints. Finally, Fx-5A exhibited sporadic non-appreciable detection of anti-Fx-5A antibodies and a dose-dependent linear toxicokinetics with T1/2 value ranges from 2.7 to 6.2 h. In conclusion, the No Observed Adverse Effect Level was considered to be 75 mg/kg/day with associated exposures average Cmax and AUC0-last of 453 μg/mL and 2232 h μg/mL, respectively, on Day 27.
Collapse
Affiliation(s)
- Mohammed Bourdi
- National Center for Advancing Translational Sciences, NIH, Rockville, MD, 20850, USA
| | - Marcelo Amar
- National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
| | - Alan T Remaley
- National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
| | - Pramod S Terse
- National Center for Advancing Translational Sciences, NIH, Rockville, MD, 20850, USA.
| |
Collapse
|
5
|
Carrier É, Houde M, Grandbois M, Bkaily G, Warner TD, D'Orléans-Juste P. Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. Can J Physiol Pharmacol 2017; 95:954-960. [PMID: 28704616 DOI: 10.1139/cjpp-2017-0314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In the present study, we assessed whether the endogenous platelet inhibitory mechanisms are altered in the early to moderate stages of the atherosclerotic process. Apolipoprotein E deficient mice (ApoE-/-), a mouse model of atherosclerosis, and their wild-type (WT) counterparts were used to assess agonist-stimulated synthesis of prostacyclin (PGI2), inhibition of platelet aggregation ex vivo, and intra-platelet cAMP levels. Basal U46619 and ADP -induced platelet aggregation in vitro were increased in ApoE-/- mice at 18-20 weeks in comparison with 8-10 weeks of age. Systemically administered endothelin-1 (ET-1) or bradykinin (BK) inhibited platelet aggregation in a similar fashion in 8- to 10-week-old ApoE-/- and WT mice, but not in the ApoE-/- mice at 18-20 weeks of age, although both peptides maintained their capacity to increase plasma levels of the PGI2. Intravenous infusion of PGI2 also failed to inhibit platelet aggregation ex vivo in 18- to 20-week-old ApoE-/- mice. Interestingly, both BK and PGI2 retained their ability to increase intraplatelet cAMP in WT and ApoE-/- mice. Our results suggest that a loss of activity of endogenous inhibitorymechanisms could contribute to the increased platelet reactivity in ApoE-/- mice, and that this phenomenon occurs early in the intermediate stage of the atherosclerotic process.
Collapse
Affiliation(s)
- É Carrier
- a Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC J1H 5N4, Canada
| | - M Houde
- a Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC J1H 5N4, Canada
| | - M Grandbois
- a Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC J1H 5N4, Canada
| | - G Bkaily
- b Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
| | - T D Warner
- c The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - P D'Orléans-Juste
- a Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC J1H 5N4, Canada
| |
Collapse
|
6
|
Abstract
The concept of lipoprotein mimetics was developed and extensively tested in the last three decades. Most lipoprotein mimetics were designed to recreate one or several functions of high-density lipoprotein (HDL) in the context of cardiovascular disease; however, the application of this approach is much broader. Lipoprotein mimetics should not just be seen as a set of compounds aimed at replenishing a deficiency or dysfunctionality of individual elements of lipoprotein metabolism but rather as a designer concept with remarkable flexibility and numerous applications in medicine and biology. In the present review, we discuss the fundamental design principles used to create lipoprotein mimetics, mechanisms of their action, medical indications and efficacy in animal models and human studies.
Collapse
|
7
|
Abstract
A small library of truncated/lipid-conjugated neuromedin U (NmU) analogs was synthesized and tested in vitro using an intracellular calcium signaling assay. The selected, most active analogs were then tested in vivo, and showed potent anorexigenic effects in a diet-induced obese (DIO) mouse model. The most promising compound, NM4-C16 was effective in a once-weekly-dose regimen. Collectively, our findings suggest that short, lipidated analogs of NmU are suitable leads for the development of novel anti-obesity therapeutics.
Collapse
|
8
|
Li R, Navab K, Hough G, Daher N, Zhang M, Mittelstein D, Lee K, Pakbin P, Saffari A, Bhetraratana M, Sulaiman D, Beebe T, Wu L, Jen N, Wine E, Tseng CH, Araujo JA, Fogelman A, Sioutas C, Navab M, Hsiai TK. Effect of exposure to atmospheric ultrafine particles on production of free fatty acids and lipid metabolites in the mouse small intestine. ENVIRONMENTAL HEALTH PERSPECTIVES 2015; 123:34-41. [PMID: 25170928 PMCID: PMC4286268 DOI: 10.1289/ehp.1307036] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 08/27/2014] [Indexed: 05/09/2023]
Abstract
BACKGROUND Exposure to ambient ultrafine particulate matter (UFP) is a well-recognized risk factor for cardiovascular and respiratory diseases. However, little is known about the effects of air pollution on gastrointestinal disorders. OBJECTIVE We sought to assess whether exposure to ambient UFP (diameter < 180 nm) increased free fatty acids and lipid metabolites in the mouse small intestine. METHODS Ldlr-null mice were exposed to filtered air (FA) or UFP collected at an urban Los Angeles, California, site that was heavily affected by vehicular emissions; the exposure was carried out for 10 weeks in the presence or absence of D-4F, an apolipoprotein A-I mimetic peptide with antioxidant and anti-inflammation properties on a high-fat or normal chow diet. RESULTS Compared with FA, exposure to UFP significantly increased intestinal hydroxyeicosatetraenoic acids (HETEs), including 15-HETE, 12-HETE, 5-HETE, as well as hydroxyoctadecadienoic acids (HODEs), including 13-HODE and 9-HODE. Arachidonic acid (AA) and prostaglandin D2 (PGD2) as well as some of the lysophosphatidic acids (LPA) in the small intestine were also increased in response to UFP exposure. Administration of D-4F significantly reduced UFP-mediated increase in HETEs, HODEs, AA, PGD2, and LPA. Although exposure to UFP further led to shortened villus length accompanied by prominent macrophage and neutrophil infiltration into the intestinal villi, administration of D-4F mitigated macrophage infiltration. CONCLUSIONS Exposure to UFP promotes lipid metabolism, villus shortening, and inflammatory responses in mouse small intestine, whereas administration of D-4F attenuated these effects. Our findings provide a basis to further assess the mechanisms underlying UFP-mediated lipid metabolism in the digestive system with clinical relevance to gut homeostasis and diseases.
Collapse
Affiliation(s)
- Rongsong Li
- Division of Cardiology, Department of Medicine, School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Yin K, Agrawal DK. High-density lipoprotein: a novel target for antirestenosis therapy. Clin Transl Sci 2014; 7:500-11. [PMID: 25043950 DOI: 10.1111/cts.12186] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Restenosis is an integral pathological process central to the recurrent vessel narrowing after interventional procedures. Although the mechanisms for restenosis are diverse in different pathological conditions, endothelial dysfunction, inflammation, vascular smooth muscle cell (SMC) proliferation, and myofibroblasts transition have been thought to play crucial role in the development of restenosis. Indeed, there is an inverse relationship between high-density lipoprotein (HDL) levels and risk for coronary heart disease (CHD). However, relatively studies on the direct assessment of HDL effect on restenosis are limited. In addition to involvement in the cholesterol reverse transport, many vascular protective effects of HDL, including protection of endothelium, antiinflammation, antithrombus actions, inhibition of SMC proliferation, and regulation by adventitial effects may contribute to the inhibition of restenosis, though the exact relationships between HDL and restenosis remain to be elucidated. This review summarizes the vascular protective effects of HDL, emphasizing the potential role of HDL in intimal hyperplasia and vascular remodeling, which may provide novel prophylactic and therapeutic strategies for antirestenosis.
Collapse
Affiliation(s)
- Kai Yin
- Center for Clinical & Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
| | | |
Collapse
|
10
|
Gale SC, Gao L, Mikacenic C, Coyle SM, Rafaels N, Murray Dudenkov T, Madenspacher JH, Draper DW, Ge W, Aloor JJ, Azzam KM, Lai L, Blackshear PJ, Calvano SE, Barnes KC, Lowry SF, Corbett S, Wurfel MM, Fessler MB. APOε4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol 2014; 134:127-34. [PMID: 24655576 PMCID: PMC4125509 DOI: 10.1016/j.jaci.2014.01.032] [Citation(s) in RCA: 126] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Revised: 01/08/2014] [Accepted: 01/20/2014] [Indexed: 01/28/2023]
Abstract
BACKGROUND The genetic determinants of the human innate immune response are poorly understood. Apolipoprotein (Apo) E, a lipid-trafficking protein that affects inflammation, has well-described wild-type (ε3) and disease-associated (ε2 and ε4) alleles, but its connection to human innate immunity is undefined. OBJECTIVE We sought to define the relationship of APOε4 to the human innate immune response. METHODS We evaluated APOε4 in several functional models of the human innate immune response, including intravenous LPS challenge in human subjects, and assessed APOε4 association to organ injury in patients with severe sepsis, a disease driven by dysregulated innate immunity. RESULTS Whole blood from healthy APOε3/APOε4 volunteers induced higher cytokine levels on ex vivo stimulation with Toll-like receptor (TLR) 2, TLR4, or TLR5 ligands than blood from APOε3/APOε3 patients, whereas TLR7/8 responses were similar. This was associated with increased lipid rafts in APOε3/APOε4 monocytes. By contrast, APOε3/APOε3 and APOε3/APOε4 serum neutralized LPS equivalently and supported similar LPS responses in Apoe-deficient macrophages, arguing against a differential role for secretory APOE4 protein. After intravenous LPS, APOε3/APOε4 patients had higher hyperthermia and plasma TNF-α levels and earlier plasma IL-6 than APOε3/APOε3 patients. APOE4-targeted replacement mice displayed enhanced hypothermia, plasma cytokines, and hepatic injury and altered splenic lymphocyte apoptosis after systemic LPS compared with APOE3 counterparts. In a cohort of 828 patients with severe sepsis, APOε4 was associated with increased coagulation system failure among European American patients. CONCLUSIONS APOε4 is a determinant of the human innate immune response to multiple TLR ligands and associates with altered patterns of organ injury in human sepsis.
Collapse
Affiliation(s)
- Stephen C Gale
- Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
| | - Li Gao
- Department of Medicine, Johns Hopkins University, Baltimore, Md
| | | | - Susette M Coyle
- Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
| | | | | | - Jennifer H Madenspacher
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - David W Draper
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - William Ge
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - Jim J Aloor
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - Kathleen M Azzam
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - Lihua Lai
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - Perry J Blackshear
- Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC
| | - Steven E Calvano
- Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
| | | | - Stephen F Lowry
- Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
| | - Siobhan Corbett
- Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
| | - Mark M Wurfel
- Department of Medicine, University of Washington, Seattle, Wash
| | - Michael B Fessler
- Laboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC.
| |
Collapse
|
11
|
Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, Navab M, Provencher S, Fogelman AM, Bonnet S, Reddy ST, Eghbali M. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 2014; 130:776-85. [PMID: 24963038 DOI: 10.1161/circulationaha.114.007405] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Pulmonary arterial hypertension is a chronic lung disease associated with severe pulmonary vascular changes. A pathogenic role of oxidized lipids such as hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids is well established in vascular disease. Apolipoprotein A-I mimetic peptides, including 4F, have been reported to reduce levels of these oxidized lipids and improve vascular disease. However, the role of oxidized lipids in the progression of pulmonary arterial hypertension and the therapeutic action of 4F in pulmonary arterial hypertension are not well established. METHODS AND RESULTS We studied 2 different rodent models of pulmonary hypertension (PH): a monocrotaline rat model and a hypoxia mouse model. Plasma levels of hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids were significantly elevated in PH. 4F treatment reduced these levels and rescued preexisting PH in both models. MicroRNA analysis revealed that microRNA-193-3p (miR193) was significantly downregulated in the lung tissue and serum from both patients with pulmonary arterial hypertension and rodents with PH. In vivo miR193 overexpression in the lungs rescued preexisting PH and resulted in downregulation of lipoxygenases and insulin-like growth factor-1 receptor. 4F restored PH-induced miR193 expression via transcription factor retinoid X receptor α. CONCLUSIONS These studies establish the importance of microRNAs as downstream effectors of an apolipoprotein A-I mimetic peptide in the rescue of PH and suggest that treatment with apolipoprotein A-I mimetic peptides or miR193 may have therapeutic value.
Collapse
Affiliation(s)
- Salil Sharma
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Soban Umar
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Francois Potus
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Andrea Iorga
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Gabriel Wong
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - David Meriwether
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Sandra Breuils-Bonnet
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Denise Mai
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Kaveh Navab
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - David Ross
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Mohamad Navab
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Steeve Provencher
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Alan M Fogelman
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Sébastien Bonnet
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Srinivasa T Reddy
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.)
| | - Mansoureh Eghbali
- From the Department of Anesthesiology, Division of Molecular Medicine (S.S., S.U., A.I., G.W., D. Mai, K.N., M.E.), Department of Medicine, Division of Cardiology (D. Meriwether, K.N., M.N., A.M.F., S.T.R.), Division of Pulmonary Critical Care Medicine (D.R.), Department of Molecular and Medical Pharmacology (S.T.R.), and Cardiovascular Research Laboratories (M.E.), David Geffen School of Medicine at University of California-Los Angeles; and Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, Canada (F.P., S.B.-B., S.P., S.B.).
| |
Collapse
|
12
|
Zimman A, Titz B, Komisopoulou E, Biswas S, Graeber TG, Podrez EA. Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin. PLoS One 2014; 9:e84488. [PMID: 24400094 PMCID: PMC3882224 DOI: 10.1371/journal.pone.0084488] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 11/15/2013] [Indexed: 11/19/2022] Open
Abstract
Specific oxidized phospholipids (oxPCCD36) promote platelet hyper-reactivity and thrombosis in hyperlipidemia via the scavenger receptor CD36, however the signaling pathway(s) induced in platelets by oxPCCD36 are not well defined. We have employed mass spectrometry-based tyrosine, serine, and threonine phosphoproteomics for the unbiased analysis of platelet signaling pathways induced by oxPCCD36 as well as by the strong physiological agonist thrombin. oxPCCD36 and thrombin induced differential phosphorylation of 115 proteins (162 phosphorylation sites) and 181 proteins (334 phosphorylation sites) respectively. Most of the phosphoproteome changes induced by either agonist have never been reported in platelets; thus they provide candidates in the study of platelet signaling. Bioinformatic analyses of protein phosphorylation dependent responses were used to categorize preferential motifs for (de)phosphorylation, predict pathways and kinase activity, and construct a phosphoproteome network regulating integrin activation. A putative signaling pathway involving Src-family kinases, SYK, and PLCγ2 was identified in platelets activated by oxPCCD36. Subsequent ex vivo studies in human platelets demonstrated that this pathway is downstream of the scavenger receptor CD36 and is critical for platelet activation by oxPCCD36. Our results provide multiple insights into the mechanism of platelet activation and specifically in platelet regulation by oxPCCD36.
Collapse
Affiliation(s)
- Alejandro Zimman
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
| | - Bjoern Titz
- Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
| | - Evangelia Komisopoulou
- Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
| | - Sudipta Biswas
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
| | - Thomas G. Graeber
- Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Institute for Molecular Medicine, Jonsson Comprehensive Cancer Center and California NanoSystems Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
| | - Eugene A. Podrez
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
- * E-mail:
| |
Collapse
|
13
|
Sharifov OF, Nayyar G, Ternovoy VV, Palgunachari MN, Garber DW, Anantharamaiah G, Gupta H. Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A. Innate Immun 2013; 20:867-80. [PMID: 24323453 DOI: 10.1177/1753425913514621] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Endotoxemia is a major cause of chronic inflammation, and is an important pathogenic factor in the development of metabolic syndrome and atherosclerosis. Human apolipoprotein E (apoE) and apoA-I are protein components of high-density lipoprotein, which have strong anti-endotoxin activity. Here, we compared anti-endotoxin activity of Ac-hE18A-NH2 and 4F peptides, modified from model amphipathic helical 18A peptide, to mimic, respectively, apoE and apoA-I properties. Ac-hE18A-NH2, stronger than 4F, inhibited endotoxin activity and disaggregated Escherichia coli 055:B5 (wild smooth serotype). Ac-hE18A-NH2 and 4F inhibited endotoxin activity of E. coli 026:B6 (rough-like serotype) to a similar degree. This suggests that Ac-hE18A-NH2 as a dual-domain molecule might interact with both the lipid A and headgroup of smooth LPS, whereas 4F binds lipid A. In C57BL/6 mice, Ac-hE18A-NH2 was superior to 4F in inhibiting the inflammatory responses mediated by E. coli 055:B5, but not E. coli 026:B6. However, in THP-1 cells, isolated human primary leukocytes, and whole human blood, Ac-hE18A-NH2 reduced responses more strongly than 4F to both E. coli serotypes either when peptides were pre-incubated or co-incubated with LPS, indicating that Ac-hE18A-NH2 also has strong anti-inflammatory effects independent of endotoxin-neutralizing properties. In conclusion, Ac-hE18A-NH2 is more effective than 4F in inhibiting LPS-mediated inflammation, which opens prospective clinical applications for Ac-hE18A-NH2.
Collapse
Affiliation(s)
- Oleg F Sharifov
- Department of Medicine, University of Alabama at Birmingham, AL, USA
| | - Gaurav Nayyar
- Department of Medicine, University of Alabama at Birmingham, AL, USA
| | | | | | - David W Garber
- Department of Medicine, University of Alabama at Birmingham, AL, USA
| | - Gm Anantharamaiah
- Department of Medicine, University of Alabama at Birmingham, AL, USA Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, AL, USA
| | - Himanshu Gupta
- Department of Medicine, University of Alabama at Birmingham, AL, USA VA Medical Center, Birmingham, AL, USA
| |
Collapse
|
14
|
Li R, Navab M, Pakbin P, Ning Z, Navab K, Hough G, Morgan TE, Finch CE, Araujo JA, Fogelman AM, Sioutas C, Hsiai T. Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice. J Lipid Res 2013; 54:1608-1615. [PMID: 23564731 DOI: 10.1194/jlr.m035014] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Exposure to ambient particulate matter (PM) is a risk factor for cardiovascular diseases. The redox-active ultrafine particles (UFPs) promote vascular oxidative stress and inflammatory responses. We hypothesized that UFPs modulated lipid metabolism and anti-oxidant capacity of high density lipoprotein (HDL) with an implication in atherosclerotic lesion size. Fat-fed low density lipoprotein receptor-null (LDLR⁻/⁻ mice were exposed to filtered air (FA) or UFPs for 10 weeks with or without administering an apolipoprotein A-I mimetic peptide made of D-amino acids, D-4F. LDLR⁻/⁻ mice exposed to UFPs developed a reduced plasma HDL level (P < 0.01), paraoxonase activity (P < 0.01), and HDL anti-oxidant capacity (P < 0.05); but increased LDL oxidation, free oxidized fatty acids, triglycerides, serum amyloid A (P < 0.05), and tumor necrosis factor α (P < 0.05), accompanied by a 62% increase in the atherosclerotic lesion ratio of the en face aortic staining and a 220% increase in the cross-sectional lesion area of the aortic sinus (P < 0.001). D-4F administration significantly attenuated these changes. UFP exposure promoted pro-atherogenic lipid metabolism and reduced HDL anti-oxidant capacity in fat-fed LDLR⁻/⁻ mice, associated with a greater atherosclerotic lesion size compared with FA-exposed animals. D-4F attenuated UFP-mediated pro-atherogenic effects, suggesting the role of lipid oxidation underlying UFP-mediated atherosclerosis.
Collapse
Affiliation(s)
- Rongsong Li
- Department of Biomedical Engineering, University of Southern California, Los Angeles, CA; Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and
| | - Mohamad Navab
- Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and
| | - Payam Pakbin
- Department of Civil Engineering and Environmental Science, and University of Southern California, Los Angeles, CA
| | - Zhi Ning
- School of Energy and Environment, City University of Hong Kong, Hong Kong
| | - Kaveh Navab
- Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and
| | - Greg Hough
- Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and
| | - Todd E Morgan
- Davis School of Gerontology, University of Southern California, Los Angeles, CA
| | - Caleb E Finch
- Davis School of Gerontology, University of Southern California, Los Angeles, CA
| | - Jesus A Araujo
- Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and
| | - Alan M Fogelman
- Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and
| | - Constantinos Sioutas
- Department of Civil Engineering and Environmental Science, and University of Southern California, Los Angeles, CA
| | - Tzung Hsiai
- Department of Biomedical Engineering, University of Southern California, Los Angeles, CA; Division of Cardiology, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA; and.
| |
Collapse
|
15
|
Mild hypercholesterolemia blunts the proinflammatory and prothrombotic effects of hypertension on the cerebral microcirculation. J Cereb Blood Flow Metab 2013; 33:483-9. [PMID: 23281427 PMCID: PMC3618387 DOI: 10.1038/jcbfm.2012.194] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Although an increased leukocyte and platelet adhesion is observed in cerebral venules of mice with either hypertension (HTN) or hypercholesterolemia (HCh), it remains unclear whether the combination of HTN and HCh exerts a comparable effect on leukocyte and platelet recruitment in the cerebral microvasculature. Thus, we examined whether HCh alters platelet and leukocyte adhesion, and blood-brain barrier (BBB) permeability, in cerebral venules in two models of murine HTN: DOCA salt-induced and angiotensin II (Ang II) induced. In both models, the mice were placed on either a normal or cholesterol-enriched diet. An enhanced recruitment of adherent leukocytes and platelets in cerebral venules was noted in both HTN models in the absence of HCh, but not in its presence. The Ang II-induced increase in BBB permeability was attenuated by HCh as well. Both total and high-density lipoprotein (HDL) cholesterol levels were elevated in the HCh mice. The HTN-induced increase in leukocyte and platelet adhesion was attenuated in apolipoprotein A-I transgenic mice (ApoA1-Tg) and blunted in wild-type mice treated with the ApoA1 mimetic peptide, 4F. Our findings indicate that mild HCh significantly blunts the cerebral microvascular responses to HTN and that HDL may have a role in mediating this beneficial effect of HCh.
Collapse
|
16
|
|
17
|
Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman AM. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res 2011; 53:437-445. [PMID: 22167743 DOI: 10.1194/jlr.m023523] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
To test the hypothesis that intestine is a major site of action for D-4F, LDLR(-/-) mice were fed a Western diet (WD) and administered the peptide subcutaneously (SQ) or orally. Plasma and liver D-4F levels were 298-fold and 96-fold higher, respectively, after SQ administration, whereas peptide levels in small intestine only varied by 1.66 ± 0.33-fold. Levels of metabolites of arachidonic and linoleic acids known to bind with high affinity to D-4F were significantly reduced in intestine, liver and hepatic bile to a similar degree whether administered SQ or orally. However, levels of 20-HETE, which is known to bind the peptide with low affinity, were unchanged. D-4F treatment reduced plasma serum amyloid A (SAA) and triglyceride levels (P < 0.03) and increased HDL-cholesterol levels (P < 0.04) similarly after SQ or oral administration. Plasma levels of metabolites of arachidonic and linoleic acids significantly correlated with SAA levels (P < 0.0001). Feeding 15-HETE in chow (without WD) significantly increased plasma SAA and triglyceride levels and decreased HDL-cholesterol and paraoxonase activity (P < 0.05), all of which were significantly ameliorated by SQ D-4F (P < 0.05). We conclude that D-4F administration reduces levels of free metabolites of arachidonic and linoleic acids in the small intestine and this is associated with decreased inflammation in LDL receptor deficient mice.
Collapse
Affiliation(s)
- Mohamad Navab
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
| | - Srinivasa T Reddy
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
| | | | - Greg Hough
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - Georgette M Buga
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - Jan Danciger
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - Alan M Fogelman
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
| |
Collapse
|
18
|
Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, Kwon M, Ganapathy E, Meriwether D, Farias-Eisner R, Fogelman AM, Reddy ST. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J 2011; 75:1533-8. [PMID: 21628835 DOI: 10.1253/circj.cj-11-0460] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Although high-density lipoprotein-cholesterol (HDL-C) levels in large epidemiological studies are inversely related to the risk of coronary heart disease (CHD), increasing the level of circulating HDL-C does not necessarily decrease the risk of CHD events, CHD deaths, or mortality. HDL can act as an anti- or a pro-inflammatory molecule, depending on the context and environment. Based on a number of recent studies, it appears that the anti- or pro-inflammatory nature of HDL may be a more sensitive indicator of the presence or absence of atherosclerosis than HDL-C levels. The HDL proteome has been suggested to be a marker, and perhaps a mediator, of CHD. Apolipoprotein A-1 (apoA-I), the major protein in HDL is a selective target for oxidation by myeloperoxidase, which results in impaired HDL function. Improving HDL function through modification of its lipid and/or protein content maybe a therapeutic target for the treatment of CHD and many inflammatory disorders. HDL/apoA-I mimetic peptides may have the ability to modify the lipid and protein content of HDL and convert dysfunctional HDL to functional HDL. This review focuses on recent studies of dysfunctional HDL in animal models and human disease, and the potential of apoA-I mimetic peptides to normalize the composition and function of lipoproteins.
Collapse
Affiliation(s)
- Satoshi Imaizumi
- Department of Medicine, University of California, Los Angeles, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
The burden of atherothrombotic cardiovascular disease remains high despite currently available optimum medical therapy. To address this substantial residual risk, the development of novel therapies that attempt to harness the atheroprotective functions of HDL is a major goal. These functions include the critical role of HDL in reverse cholesterol transport, and its anti-inflammatory, antithrombotic, and antioxidant activities. Discoveries in the past decade have shed light on the complex metabolic and antiatherosclerotic pathways of HDL. These insights have fueled the development of HDL-targeted drugs, which can be classified among four different therapeutic approaches: directly augmenting apolipoprotein A-I (apo A-I) levels, such as with apo A-I infusions and upregulators of endogenous apo A-I production; indirectly augmenting apo A-I and HDL-cholesterol levels, such as through inhibition of cholesteryl ester transfer protein or endothelial lipase, or through activation of the high-affinity niacin receptor GPR109A; mimicking the functionality of apo A-I with apo A-I mimetic peptides; and enhancing steps in the reverse cholesterol transport pathway, such as via activation of the liver X receptor or of lecithin-cholesterol acyltransferase.
Collapse
Affiliation(s)
- Emil M Degoma
- Division of Cardiovascular Medicine, University of Pennsylvania, Penn Tower, 6th Floor, 3400 Spruce Street, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
20
|
Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther 2010; 130:83-91. [PMID: 21172387 DOI: 10.1016/j.pharmthera.2010.12.003] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Accepted: 12/01/2010] [Indexed: 12/13/2022]
Abstract
Apolipoprotein mimetic peptides are short synthetic peptides that share structural, as well as biological features of native apolipoproteins. The early positive clinical trials of intravenous preparations of apoA-I, the main protein component of high density lipoproteins (HDL), have stimulated great interest in the use of apolipoprotein mimetic peptides as possible therapeutic agents. Currently, there are a wide variety of apolipoprotein mimetic peptides at various stages of drug development. These peptides typically have been designed to either promote cholesterol efflux or act as anti-oxidants, but they usually exert other biological effects, such as anti-inflammatory and anti-thrombotic effects. Uncertainty about which of these biological properties is the most important for explaining their anti-atherogenic effect is a major unresolved question in the field. Structure-function studies relating the in vitro properties of these peptides to their ability to reduce atherosclerosis in animal models may uncover the best rationale for the design of these peptides and may lead to a better understanding of the mechanisms behind the atheroprotective effect of HDL.
Collapse
Affiliation(s)
- David O Osei-Hwedieh
- Lipoprotein Metabolism Section, Cardio-pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, MD, USA
| | | | | | | |
Collapse
|
21
|
Abstract
PURPOSE OF REVIEW To review published data related to the potential applicability of apolipoprotein A-I mimetic peptides. RECENT FINDINGS Despite a wealth of information on HDL-C levels and risk for cardiovascular disease (CVD), little evidence is present to suggest that raising HDL-C levels per se will result in CVD risk reduction. Rather, increasing HDL functionality might be a more successful strategy to reverse the process of atherosclerosis. In as such, apoA-I mimetic peptides, either in single or tandem formulation, hold great promise. Evidence gathered over the last years has provided insight in the extent to which mimetics influence several cardio metabolic pathways. ApoA-I mimetics have shown to have anti-inflammatory, antioxidant, and antiatherogenic effects. Direct comparisons between different mimetics have provided insight in factors influencing the differential beneficial consequences of these peptides. Data derived from recent studies suggest that mimetics might gain their position as a therapeutic intervention in the treatment of septicaemia, transplantation rejection, diabetes and auto-immune diseases. SUMMARY This review provides a summary of the current literature on the potential application of apoA-I mimetics as therapeutic agents. There is increasing evidence that these mimetics should be considered as a promising supplement to current strategies. Results from human studies addressing the in-vivo effects of the different apoA-I mimetics are eagerly awaited.
Collapse
Affiliation(s)
- G K Hovingh
- Department Vascular Medicine, Academic Medical Center, Meibergdreef 9 F4-159.2, 1100DD Amsterdam, The Netherlands.
| | | | | |
Collapse
|
22
|
Zimman A, Podrez EA. Regulation of platelet function by class B scavenger receptors in hyperlipidemia. Arterioscler Thromb Vasc Biol 2010; 30:2350-6. [PMID: 21071700 DOI: 10.1161/atvbaha.110.207498] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Platelets constitutively express class B scavenger receptors CD36 and SR-BI, 2 closely related pattern recognition receptors best known for their roles in lipoprotein and lipid metabolism. The biological role of scavenger receptors in platelets is poorly understood. However, in vitro and in vivo data suggest that class B scavenger receptors modulate platelet function and contribute significantly to thrombosis by sensing pathological or physiological ligands, inducing prothrombotic signaling, and increasing platelet reactivity. Platelet CD36 recognizes a novel family of endogenous oxidized choline phospholipids that accumulate in plasma of hyperlipidemic mice and in plasma of subjects with low high-density lipoprotein levels. This interaction leads to the activation of specific signaling pathways and promotes platelet activation and thrombosis. Platelet SR-BI, on the other hand, plays a critical role in the induction of platelet hyperreactivity and accelerated thrombosis under conditions associated with increased platelet cholesterol content. Intriguingly, oxidized high-density lipoprotein, an SR-BI ligand, can suppress platelet function. These recent findings demonstrate that platelet class B scavenger receptors play roles in thrombosis in dyslipidemia and may contribute to acute cardiovascular events in vivo in hypercholesterolemia.
Collapse
Affiliation(s)
- Alejandro Zimman
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
| | | |
Collapse
|
23
|
Amar MJA, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 2010; 334:634-41. [PMID: 20484557 DOI: 10.1124/jpet.110.167890] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Intravenous administration of apolipoprotein (apo) A-I complexed with phospholipid has been shown to rapidly reduce plaque size in both animal models and humans. Short synthetic amphipathic peptides can mimic the antiatherogenic properties of apoA-I and have been proposed as alternative therapeutic agents. In this study, we investigated the atheroprotective effect of the 5A peptide, a bihelical amphipathic peptide that specifically effluxes cholesterol from cells by ATP-binding cassette transporter 1 (ABCA1). 5A stimulated a 3.5-fold increase in ABCA1-mediated efflux from cells and an additional 2.5-fold increase after complexing it with phospholipid (1:7 mol/mol). 5A-palmitoyl oleoyl phosphatidyl choline (POPC), but not free 5A, was also found to promote cholesterol efflux by ABCG1. When incubated with human serum, 5A-POPC bound primarily to high-density lipoprotein (HDL) but also to low-density lipoprotein (LDL) and promoted the transfer of cholesterol from LDL to HDL. Twenty-four hours after intravenous injection of 5A-POPC (30 mg/kg) into apoE-knockout (KO) mice, both the cholesterol (181%) and phospholipid (219%) content of HDL significantly increased. By an in vivo cholesterol isotope dilution study and monitoring of the flux of cholesterol from radiolabeled macrophages to stool, 5A-POPC treatment was observed to increase reverse cholesterol transport. In three separate studies, 5A when complexed with various phospholipids reduced aortic plaque surface area by 29 to 53% (n = 8 per group; p < 0.02) in apoE-KO mice. No signs of toxicity from the treatment were observed during these studies. In summary, 5A promotes cholesterol efflux both in vitro and in vivo and reduces atherosclerosis in apoE-KO mice, indicating that it may be a useful alternative to apoA-I for HDL therapy.
Collapse
Affiliation(s)
- Marcelo J A Amar
- Lipoprotein Metabolism Section, Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|